Company: ARMP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001558370-25-007765
Chunk: 25

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
Item 1.  FINANCIAL STATEMENTS

Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited) 

(in thousands, except share and per share data)

​

​​​​​​​​    March 31, 2025    December 31, 2024Assets​​​​​​Current assets​​​​​​Cash and cash equivalents​$ 11,688​$ 9,291Prepaid expenses and other current assets​  1,240​  1,273Other receivables​​ 238​​ 744Total current assets​  13,166​  11,308Restricted cash​​ 5,390​​ 5,480Property and equipment, net​  12,883​  13,241Operating lease right-of-use asset​  41,090​  41,687In-process research and development​​ 10,256​​ 10,256Goodwill​​ 3,490​​ 3,490Other assets​  975​  975Total assets​$ 87,250​$ 86,437​​​​​​​Liabilities and stockholders’ deficit​   ​   Current liabilities​   ​   Accounts payable and accrued liabilities​$ 1,614​$ 2,055Accrued compensation​​ 1,347​​ 2,280Convertible Loan, current​​ 27,694​​ —Term debt, current​​ 75,089​​ 38,954Current portion of operating lease liabilities​​ 4,459​​ 4,431Other current liabilities​​ 337​​ 529Total current liabilities​  110,540​  48,249Convertible Loan, non-current​​ —​​ 32,897Term debt, non-current​​ —​​ 22,539Operating lease liabilities, net of current portion​​ 27,416​​ 27,694Deferred tax liability​​ 3,077​​ 3,077Total liabilities​  141,033​  134,456​​​​​​​Commitments and contingencies (Note 12)​   ​   Stockholders’ deficit​   ​   Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,193,479 and 36,183,067 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively​  362​  362Additional